Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma

Abstract

Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refractory disease, there is currently no standard treatment. Vinflunine, a second-generation Vinca alkaloid, is the first chemotherapeutic agent to be evaluated in a large UC second-line population. This review discusses the pre-clinical and clinical data published, and compares vinflunine to alternative single agents and combination regimens tested in this setting. Based on the results of the phase II and III clinical trials, there appears to be sufficient evidence to support the use of vinflunine in the second-line setting.

Securing the supply chain

“…Your concluding quote that 'it is better to focus on individually tailored palliative care' is taken from a single French drug bulletin 4 as opposed to numerous peer-reviewed oncology journals which conclude the contrary. [5][6][7][8][9] The conclusion of the TGA's clinical evaluator, that the vinflunine data support a positive benefit-risk balance for its approved indication in patients who have few available therapeutic options, is more reliable. 1 Jacqueline du Toit Regulatory manager Pierre Fabre Médicament Australia Pty Ltd Sydney reFerenCes…”